Neurocrine Biosciences (NBIX) Profit After Tax Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -303.53% |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | -17.27% |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 34.32% |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | -99.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.32% |
| Mar 31, 2026 | 1,682.88% |
| Dec 31, 2025 | 70.55% |
| Sep 30, 2025 | 61.94% |
| Jun 30, 2025 | 65.38% |
| Mar 31, 2025 | -72.04% |
| Dec 31, 2024 | -41.94% |
| Sep 30, 2024 | 57.33% |
| Jun 30, 2024 | -31.94% |
| Mar 31, 2024 | 151.83% |
| Dec 31, 2023 | 89.73% |
| Sep 30, 2023 | 20.44% |
| Jun 30, 2023 | 582.32% |
| Mar 31, 2023 | -651.08% |
| Dec 31, 2022 | 1,552.54% |
| Sep 30, 2022 | 204.44% |
| Jun 30, 2022 | -146.81% |
| Mar 31, 2022 | -56.70% |
| Dec 31, 2021 | -101.70% |
| Sep 30, 2021 | 138.14% |